FIT Biotech Oy
Press release [1.8.2017] at [14.00 EET]
Results from Clinical Trial with FIT Biotech's HIV Vaccine Candidate Presented at the International AIDS Society (IAS) Conference in Paris
FIT Biotech Oy ("Company") announced today that a scientific poster on a Vaccine Research Institute (VRI) clinical trial results involving the Company's HIV vaccine candidate, GTU-MultiHIV B, was presented at the 9TH IAS Conference on HIV Science in Paris, France. The title of the poster is:
Immunogenicity and safety of 4 prime-boost combinations of HIV vaccine candidates (MVA HIV-B; LIPO-5; GTU-MultiHIV B) in healthy volunteers - Inserm-ANRS VRI01 phase I/II randomized trial.
The lead author is Dr. J.-D. Lelièvre of the VRI, Inserm, University Paris-Créteil, France.
The clinical trial in the scientific poster was conducted through the VRI program (Inserm-ANRS) and enrolled HIV-negative subjects. It tested four different prime-boost regimens. The major findings are:
- The strategy of combining GTU-MultiHIVB prime and ANRS-MVA HIV-B boost met the pre-defined minimum immunogenicity criterion to pursue clinical development.
- The current understanding is that priming should be done with a DNA-vaccine and boosting with a peptide vaccine.
- These results and access to the ANRS-MVA HIV-B vaccine support the decision to test the same prime-boost combination in the EHVA (European HIV Vaccine Alliance) phase II trial in HIV-positive subjects that is planned to commence later this year.
"We are making progress towards a functional cure for HIV, and having the support of the HIV community is key for succeeding in this", commented Santeri Kiviluoto, Chief Scientific Officer. FIT Biotech is a part of a major research consortium EHVA that develops new vaccines against HIV. The project is funded by the EU Horizon 2020 framework programme.
FIT BIOTECH OY
Further information:
Santeri Kiviluoto, PhD, BSc (Econ & Bus Adm)
Chief Scientific Officer
FIT Biotech Oy
Tel: +46 76-560 71 30
E-mail: santeri.kiviluoto@fitbiotech.com
About FIT Biotech
FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.
FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.
FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.
About VRI
The Vaccine Research Institute (VRI), Laboratory of excellence, was established by the French National Agency for Research on AIDS and viral hepatitis (ANRS - France Recherche Nord & Sud Sida-HIV Hépatites) and the University of Paris-Est Créteil (UPEC) to conduct research to accelerate the development of effective vaccines against HIV/AIDS (Human Immunodeficiency Virus / Acquired ImmunoDeficiency Syndrome), HCV (Hepatitis C Virus) and emerging infectious diseases. VRI's structure strengthens the links between basic and translational research, patient associations and the socio-economic world. VRI stems from the existing ANRS vaccine research program and includes research teams with multidisciplinary expertise, a network of national and international eminent scientists, a network of clinical centers, core facilities, and industry and charitable partners. It is based at the Henri Mondor hospital, Créteil, France.
The Labex VRI is supported by the "Investissements d'Avenir" program managed by the ANR under reference ANR-10-LABX-77-01
http://vaccine-research-institute.fr/en
Press contact:
Mireille CENTLIVRE
E-mail: mireille.centlivre@u-pec.fr
Tel: +33 (0) 1 49 81 39 07
About ANRS
ANRS (French National Agency for Research on AIDS and viral hepatitis - France Recherche Nord & Sud Sida-HIV Hépatites) is the leading organization for research on the HIV/AIDS and hepatitis epidemics in France, and a leader in the fight against these diseases in developing countries. In 2012, ANRS became an autonomous agency within Inserm. ANRS objectives are to acquire and increase new knowledge in order to improve the prevention of HIV/AIDS and HCV and to care for people infected. ANRS brings together research scientists from all disciplines and doctors belonging to research organizations (Inserm, CNRS, Institut Pasteur, IRD), universities and hospitals all over France. The Agency's vaccine research program is managed by VRI (Vaccine Research Institute).
http://www.anrs.fr/